Cantargia: Video interview with CEO Göran Forsber
Redeye interviews Göran Forsberg about the new clinical development strategy for nadunolimab in pancreatic cancer with a controlled phase IIb trial instead of participating in Precision Promise.
Sign up for free to continue
Already a member?
Disclosures and disclaimers
Premium Plan required to unlock